巴克莱：高额关税或致美国药价上涨及短缺，消费者首当其冲

Core Viewpoint - Barclays analysts indicate that the proposed tariffs of up to 200% on pharmaceuticals in the U.S. could significantly impact the pharmaceutical industry, leading to increased production costs, reduced profit margins, and potential supply chain disruptions, ultimately resulting in higher drug prices for consumers [1] Group 1 - The proposed tariffs may lead to drug shortages in the U.S. market [1] - The high tariffs could compress profit margins for pharmaceutical companies [1] - A transition period of up to 18 months may be granted to companies to adjust before the tariffs are implemented, which could be a positive factor for the industry [1]